Abstract 694P
Background
4 cycles of combination chemotherapy (CTx) with High-dose P-ICE plus stem-cell support is a highly active salvage chemotherapy as shown in 37 patients (pts) with relapsed/refractory germ cell tumors (Proc ASCO 2017 #4552). Final survival data after long term follow-up are now available.
Methods
From 04/08 to 05/15 37 pts were included in this phase-II trial. Eligibility criteria: relapse or progression under one or more induction CTx, ECOG PS (0-1), Creatinine-clearance > 30ml/min, adequate liver function, measurable tumor or at least marker-elevation. Dosing & schedule: Stem cell apharesis after 1 (-2) cycles induction CTx with standard dose P-ICE (Paclitaxel 135mg/m2 d1, Ifosfamide 1500mg/m2 d1,2,3, Carboplatin 150mg/m2 d1,2,3, Etoposide 150mg/m2 d1,2,3), followed by 4 sequential cycles of High-dose P-ICE (Paclitaxel 200mg/m2 d1, Ifosfamide 3300mg/m2 d1,2,3, Carboplatin 330mg/m2 d1,2,3, Etoposide 330mg/m2 d1,2,3) plus stem cell support at d5.
Results
37 patients received standard dose induction CTx, followed by high dose CTx in 33 evaluable patients (insufficient stem cell apharesis 3 pts; medical reasons 1 pt): Seminoma (5 pts) / non-seminoma (28 pts); gonadal (27 pts) / extragonadal (6 pts); N prior CTx: 1 (26 pts) / 2 (4 pts) / 3 (3 pts); ECOG-PS: 0 (19 pts) / 1 (14 pts). Response rate: CR/NED 17 (51.5%), CR/NED/PR-/SD- with marker normalization 21 (63.6%), PD 12 (36.4%). PFS all pts: 85 (4-180) months; DFS of CR/NED: 130 (58-180) months; RFS of all favourable response: 122 (23-180) months. OS all pts: 85 (6-180) months, OS favorable response: 122 (23–180) months, unfavourable response: 14 (6-28) months. Toxicity was tolerable without unexspected toxicities or treatment related death, with grade 4 hematological toxicity in all patients, 27% grade 3-4 mucositis, 12% grade 3-4 diarrhea as most common toxicities.
Conclusions
This protocol is highly active, well tolerated and seems to be currently the most appropriate regimen for salvage CTx in advanced germ cell cancer and strongly requires further prospective investigation in this patient population.
Clinical trial identification
EudraCT 2006-00600411.
Editorial acknowledgement
Legal entity responsible for the study
Martin-Luther-Universität Halle-Wittenberg.
Funding
Amgen GmbH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1192P - Optimizing lung cancer screening: Independent verification of an AI/ML computer-aided detection and characterization software as medical device
Presenter: Sylvain Bodard
Session: Poster session 09
1194P - Development of a novel artificial intelligence (AI) algorithm to detect pulmonary nodules on chest radiography
Presenter: Mitsunori Higuchi
Session: Poster session 09
1195P - Whole-body magnetic resonance imaging (WB-MRI) screening in Li Fraumeni syndrome for early cancer diagnosis: The SIGNIFIED project
Presenter: Elena Cojocaru
Session: Poster session 09
1196P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting adjuvant therapy outcomes in ovarian cancer patients
Presenter: Dong Woo Lee
Session: Poster session 09
1197P - Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer
Presenter: Debbie Robbrecht
Session: Poster session 09
1198P - Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Presenter: Pontis Julien
Session: Poster session 09